Navigation Links
High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
Date:5/20/2008

Procedural growth could increase by more than 20% over the next five years,

according to Millennium Research Group

WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the thoracic aortic stent graft market is poised to exceed 20% growth over the next five years. Carotid stents are another PV device segment with significant potential, although market expansion in this area is dependent on positive clinical trial data and expanded Centers for Medicare & Medicaid Services (CMS) reimbursement.

Treatment of thoracic aortic disease, a PV condition, is expected to witness a surge over the next five years as manufacturers focus on developing aortic stent grafts specific to this indication. The thoracic aorta is extremely risky to treat surgically because of the high mortality associated with this procedure; thus, the availability of a minimally invasive alternative -- thoracic endovascular aortic repair (TEVAR)-- has garnered a lot of attention among physicians and represents a significant opportunity for market expansion. Next-generation thoracic stent grafts, and clinical trials supporting their efficacy, will expand the treatable patient population, leading to growth in procedures in excess of 20% over the next five years.

Growth in carotid artery stenting procedures slowed to less than 5% per year in 2007 due to a lack of conclusive data supporting the safety and efficacy of the procedure compared to surgical alternatives. Compounding this lack was the CMS decision to not expand reimbursement coverage to include select asymptomatic carotid artery disease patients. In early 2008, CMS decided, however, to reexamine the expansion to reimbursement. If expanded reimbursement is approved, and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) trial yields favorable results for stenting, carotid stenting growth could jump to greater than 20% before 2012.

"Our market forecasts present variable growth models," says Stephanie LaBelle, Analyst at Millennium Research Group. "These models consider the potential expansion of carotid stenting reimbursement, the completion of CREST, a large randomized clinical study comparing the efficacy of carotid artery stenting versus carotid endarterectomy, and the release of post-market carotid stenting surveillance data. These forecasts are supported by a survey of US physicians who rated expanded CMS reimbursement as the factor that would have the largest impact on growth in carotid stenting procedures; the release of clinical trial data supporting carotid artery stenting was rated second-most important."

The US Markets for Peripheral Vascular Devices 2008 report provides coverage of all key industry competitors, including Abbott Vascular, AngioDynamics, B. Braun, Boston Scientific, Cook Medical, Cordis, C. R. Bard, ev3, Medtronic, W. L. Gore, and Terumo, among others. Global coverage of this report includes Europe, Asia-Pacific, Latin America, Canada, and Japan.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
2. Diabetes Drugs Emerge as Top Force in Drug Spending Growth
3. Amil Has Strong Growth With High Profitability
4. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
5. New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate
6. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
7. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
8. Booth Joins PrePak Systems for Growth, Expansion
9. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
10. Some Weight-Loss Drugs Might Disrupt Brain Growth in Kids
11. Symposium Targets Critical Manufacturing Topics for Emerging Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: